Xeris Biopharma Holdings (FRA:2B30) Cash Flow from Discontinued Operations : €0.0 Mil (TTM As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Xeris Biopharma Holdings Cash Flow from Discontinued Operations?

Cash flow from discontinued operations is the cash received by a company that comes from the sale of part of business.

Xeris Biopharma Holdings's cash flow from discontinued operations for the three months ended in Jun. 2024 was €0.0 Mil. It means Xeris Biopharma Holdings received €0.0 Mil from the sale of part of business quarterly. Xeris Biopharma Holdings's cash flow from discontinued operations for the trailing twelve months (TTM) ended in Jun. 2024 was €0.0 Mil.

Xeris Biopharma Holdings Cash Flow from Discontinued Operations Historical Data

The historical data trend for Xeris Biopharma Holdings's Cash Flow from Discontinued Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xeris Biopharma Holdings Cash Flow from Discontinued Operations Chart

Xeris Biopharma Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow from Discontinued Operations

Get a 7-Day Free Trial

Xeris Biopharma Holdings Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Cash Flow from Discontinued Operations	Get a 7-Day Free Trial															-	-	-	-	-

Xeris Biopharma Holdings Cash Flow from Discontinued Operations Calculation

Cash received by a company that comes from the sale of part of business.

Cash Flow from Discontinued Operations for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

Xeris Biopharma Holdings Cash Flow from Discontinued Operations Related Terms

Thank you for viewing the detailed overview of Xeris Biopharma Holdings's Cash Flow from Discontinued Operations provided by GuruFocus.com. Please click on the following links to see related term pages.

Xeris Biopharma Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (FRA:2B30) » Definitions » Cash Flow from Discontinued Operations

Comparable Companies

Traded in Other Exchanges

XERS:USA 0A8E:UK

Address

180 North LaSalle Street, Suite 1600, Chicago, IL, USA, 60601

Website

https://www.xerispharma.com

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.

Xeris Biopharma Holdings Headlines

No Headlines